Statin prescription among patients with type 2 diabetes in Botswana: findings and implications.
Adult
Biomarkers
/ analysis
Blood Glucose
/ analysis
Botswana
/ epidemiology
Cardiovascular Diseases
/ prevention & control
Diabetes Mellitus, Type 2
/ drug therapy
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Male
Middle Aged
Odds Ratio
Practice Guidelines as Topic
/ standards
Prognosis
Prescription and Botswana
Statin
Type 2 diabetes mellitus
Journal
BMC endocrine disorders
ISSN: 1472-6823
Titre abrégé: BMC Endocr Disord
Pays: England
ID NLM: 101088676
Informations de publication
Date de publication:
10 Mar 2020
10 Mar 2020
Historique:
received:
24
06
2019
accepted:
27
02
2020
entrez:
11
3
2020
pubmed:
11
3
2020
medline:
26
11
2020
Statut:
epublish
Résumé
There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana. The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescriptions. Overall, 477 (95.4%) participants were eligible for a statin prescription. Clinicians prescribed statins in 217 (45.5%) of eligible participants, and only one (4.4%) ineligible participant. The probability of a statin prescription was higher in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17-1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00-1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06-1.74). A large proportion with type 2 diabetes in Gaborone is not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescriptions. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations.
Sections du résumé
BACKGROUND
BACKGROUND
There is evidence of statin benefit among patients with diabetes regardless of cholesterol levels or prior cardiovascular disease history. Despite the evidence, there is under-prescription of statins in clinical practice. This study aimed to assess statin prescriptions and associated factors among patients with type 2 diabetes in Botswana.
METHODS
METHODS
The study was a secondary data analysis of 500 randomly selected type 2 diabetes patients at a specialised diabetes clinic at Gaborone, Botswana. We assessed the proportion of statin-eligible patients who are prescribed statins and evaluated the adjusted associations between various factors and statin prescriptions.
RESULTS
RESULTS
Overall, 477 (95.4%) participants were eligible for a statin prescription. Clinicians prescribed statins in 217 (45.5%) of eligible participants, and only one (4.4%) ineligible participant. The probability of a statin prescription was higher in participants with high baseline low-density lipoprotein cholesterol (risk ratio [RR]: 1.49; 95%CI: 1.17-1.89), increasing duration of diabetes (RR: 1.01; 95%CI 1.00-1.03) and the presence of chronic kidney disease (RR: 1.35; 95%CI: 1.06-1.74).
CONCLUSION
CONCLUSIONS
A large proportion with type 2 diabetes in Gaborone is not receiving statins. Clinicians did not consider most guideline-recommended indications for statin prescriptions. The findings call for improvement in diabetes quality of care by implementing evidence-based guideline recommendations.
Identifiants
pubmed: 32151249
doi: 10.1186/s12902-020-0516-7
pii: 10.1186/s12902-020-0516-7
pmc: PMC7063760
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Références
Prev Med. 2015 Sep;78:1-8
pubmed: 26051202
Circulation. 2006 Feb 14;113(6):791-8
pubmed: 16461820
BMJ. 2006 Jan 14;332(7533):73-8
pubmed: 16371403
Lancet. 2003 Jun 14;361(9374):2005-16
pubmed: 12814710
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
J Am Soc Nephrol. 2005 Dec;16(12):3748-54
pubmed: 16251235
Am J Clin Nutr. 1998 Oct;68(4):899-917
pubmed: 9771869
Eur Heart J. 2012 Jul;33(13):1635-701
pubmed: 22555213
Diabetes Care. 2005 May;28(5):1151-7
pubmed: 15855581
Cardiovasc Diabetol. 2009 May 13;8:25
pubmed: 19439071
Cardiovasc Diabetol. 2016 Jan 25;15:14
pubmed: 26809442
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
Neth J Med. 2015 Aug;73(7):316-23
pubmed: 26314714
Clin Cardiol. 2017 Mar;40(3):155-162
pubmed: 28026031
J Diabetes. 2018 Sep;10(9):699-707
pubmed: 29658177
Value Health. 2015 Sep;18(6):896-905
pubmed: 26409618
Prev Cardiol. 2009 Spring;12(2):95-101
pubmed: 19476583
BMC Cardiovasc Disord. 2013 Aug 02;13:54
pubmed: 23915151
Eur J Clin Pharmacol. 2009 Oct;65(10):1013-24
pubmed: 19529927
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Lancet. 2009 Jan 17;373(9659):240-9
pubmed: 19042012
Drugs. 2012 Dec 24;72(18):2365-73
pubmed: 23186103
BMJ. 2003 Jun 28;326(7404):1423
pubmed: 12829554
Cardiovasc J Afr. 2017 Mar/Apr 23;28(2):112-117
pubmed: 27701482
Front Pharmacol. 2011 Jan 07;1:141
pubmed: 21833180
Diabet Med. 2014 Dec;31(12):1577-85
pubmed: 25185778
Lancet. 2010 Feb 27;375(9716):735-42
pubmed: 20167359
PLoS One. 2016 Mar 01;11(3):e0150033
pubmed: 26930050
Endocr Pract. 2017 Oct;23(10):1232-1253
pubmed: 28816530
Indian J Endocrinol Metab. 2012 Jul;16(4):558-64
pubmed: 22837916
J Am Soc Nephrol. 1993 Nov;4(5):1159-71
pubmed: 8305642
Pharmacy (Basel). 2016 Oct 28;4(4):
pubmed: 28970408
Diabetes Res Clin Pract. 2012 Jan;95(1):30-6
pubmed: 22071431
PLoS One. 2011 Apr 29;6(4):e18744
pubmed: 21559521
BMC Endocr Disord. 2011 Dec 20;11:19
pubmed: 22185229
BMJ Open. 2019 Jul 23;9(7):e026807
pubmed: 31340960
J Diabetes Res. 2016;2016:4968350
pubmed: 27738638
Cardiovasc Drugs Ther. 2018 Aug;32(4):397-404
pubmed: 30062465
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Clin Diabetes. 2017 Jan;35(1):5-26
pubmed: 28144042
J Clin Epidemiol. 1996 Feb;49(2):223-33
pubmed: 8606324
Kidney Int. 2002 Jan;61(1):297-304
pubmed: 11786112
Int J Epidemiol. 2014 Feb;43(1):116-28
pubmed: 24505082
Aging Male. 2019 Sep;22(3):169-176
pubmed: 30879380
East Afr J Public Health. 2012 Jun;9(2):70-3
pubmed: 23139960
Patient Educ Couns. 2008 Aug;72(2):311-9
pubmed: 18406562
Can J Cardiol. 2012 Sep-Oct;28(5):574-80
pubmed: 22884278
JAMA. 2015 Jul 7;314(1):52-60
pubmed: 26151266
Lancet. 2004 Aug 21-27;364(9435):685-96
pubmed: 15325833
SAGE Open Med. 2017 Sep 12;5:2050312117731473
pubmed: 28932397
Diabetes Obes Metab. 2007 Jul;9(4):455-63
pubmed: 17587387
Pan Afr Med J. 2014 Apr 07;17:252
pubmed: 25309652
Ann Intern Med. 2006 Oct 3;145(7):520-30
pubmed: 17015870
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
Lancet. 2008 Jan 12;371(9607):117-25
pubmed: 18191683